Evidence map›Paper›PMID 34365555›Full record

ArticleInflammopharmacology2021

Acteoside isolated from Colebrookea oppositifolia attenuates I/R brain injury in Wistar rats via modulation of HIF-1α, NF-κB, and VEGF pathways.

Gollapalle Lakshminarayanashastry Viswanatha, Hanumanthappa Shylaja, Krishnadas Nandakumar, Subbanna Rajesh, C H K V L S N Anjana Male

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The pharmacokinetic property and pharmacological activity of acteoside: A review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Gollapalle Lakshminarayanashastry ViswanathaIndependent Researcher, No. 387/511/A, Megalabeedi, Kengeri, Bangalore, 560060, India. glv_000@yahoo.com.
Hanumanthappa ShylajaIndependent Researcher, Kengeri, Bangalore, 560060, India.
Krishnadas NandakumarDepartment of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, India.
Subbanna RajeshDepartment of Pharmacology, Government College of Pharmacy, Bangalore, 560027, India.
C H K V L S N Anjana MaleDepartment of Pharmaceutical Chemistry and Phytochemistry, Nirmala College of Pharmacy, Mangalagiri, 522503, India.
Manipal Academy of Higher Education · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe objective of this study was to assess the anti-stroke activity of acteoside isolated from methanolic root extract of C. oppositifolia

methodsIschemia-reperfusion(I/R) brain injury was induced in Wistar rats to assess the anti-stroke activity of acteoside. Rats were pretreated with acteoside (10, 25 & 50 mg/kg, p.o.) before the induction of I/R injury. Parameters such as neurological, motor-cognitive functions were evaluated along with morphological (brain volume, infarct size), biochemical (SOD, Catalase, GSH, lipid peroxidation, TNF-α, IL-6, IL-10, ICAM-1, HIF-1α, VEGF, and NF-κB), histopathological, and gene expression studies (HIF-1α, VEGF) were performed to study the protective effect of acteoside against I/R induced brain injury.

resultsI/R injury caused significant deterioration of neurological (p < 0.01), motor (p < 0.01) and cognitive (p < 0.01) functions, associated with increase in the brain volume (p < 0.01), and infarct size (p < 0.01); increase in the levels of MDA, TNF-α, IL-6, ICAM-1, HIF-1α, VEGF, and NF-κB along with significant decrease in SOD, catalase, GSH, and IL-10 (p < 0.01 for all parameters) compared to Sham control group. Histology of brain tissue of disease control group exhibited significant vascular changes, neutrophil infiltration, cerebral oedema, and necrosis of the neuronal cells. Further, the gene-expression studies showed significant increase in the HIF-1α (p < 0.01) and VEGF (p < 0.01) mRNA levels in the I/R control compared to Sham control. Interestingly, the acteoside (10, 25 & 50 mg/kg) has prevented the neurological, motor and cognitive dysfunctions, along with inhibiting the morphological, biochemical, histological and gene expression changes induced by I/R-injury (p < 0.05 for 10 mg; p < 0.01 for 25 & 50 mg/kg of acteoside for all the parameters).

conclusionThese findings suggest that acteoside possess potent anti-stroke activity through modulation of HIF-1α, NF-κB, and VEGF pathway along with its potent antioxidant activity.

Indexed as

AnimalsAntioxidantsDisease Models, AnimalDose-Response Relationship, DrugGlucosidesHypoxia-Inducible Factor 1, alpha SubunitLamiaceaeMaleNF-kappa BPhenolsPlant ExtractsPolyphenolsRatsRats, WistarReperfusion InjuryStrokeacteosideAntioxidantsGlucosidesHif1a protein, ratHypoxia-Inducible Factor 1, alpha SubunitNF-kappa BPhenolsPlant ExtractsPolyphenolsVascular Endothelial Growth Factor Avascular endothelial growth factor A, ratActeosideColebrookea oppositifoliaHypoxia-inducible factor 1-alpha (HIF-1α)Ischemic strokeNuclear factor-kappa-B (NF-κB)Vascular endothelia growth factor (VEGF)

Identifiers

PMID34365555
OpenAlexW3187238349

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.